Gloucester Pharmaceuticals Appoints Pharmaceutical Veteran, Donald Hayden, as Vice-Chairman.

CAMBRIDGE, Mass. -- Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today the appointment of Donald Hayden as Vice-Chairman of the company's Board of Directors. Mr. Hayden brings broad operational experience and perspective gained through a successful 25-year career at Bristol-Myers Squibb Company, including 15 years in senior executive positions.

"We are pleased that Don has chosen to join our Board as Vice-Chairman," said Martin Vogelbaum, Chairman of Gloucester's Board of Directors and Partner at Rho Ventures. "His extensive pharmaceutical development and commercialization experience, especially in oncology, will be invaluable to Gloucester as our lead HDAC inhibitor, romidepsin, progresses from the clinic to the market."

"HDAC inhibitors represent one of the most exciting new approaches in cancer therapy and I believe that romidepsin has the potential to be the best-in-class treatment in this emerging therapeutic area," said Mr. Hayden. "I look forward to working with the Gloucester team to maximize romidepsin's clinical and commercial success."

At Bristol-Myers Squibb, Mr. Hayden served as executive vice-president and president, Americas, overseeing two major pharmaceutical units and two healthcare businesses with combined annual sales in excess of $10 billion as well as global pharmaceutical manufacturing. Prior to that, Mr. Hayden held a number of senior management positions including vice-president and general manager of Mead Johnson Laboratories; president of Oncology and Immunology; senior vice-president for Worldwide Franchise Management and Business Development, Pharmaceuticals; president of Worldwide Medicines; executive vice-president of Strategy; and executive vice-president of the Health Care Group. Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

About Romidepsin

Romidepsin is a novel agent in a new class of anti-cancer drugs known as histone deacetylase inhibitors. The Company is conducting a pivotal phase II study of romidepsin for patients with cutaneous T-cell lymphoma (CTCL) and has initiated a pivotal phase II study for patients with peripheral T-cell lymphoma (PTCL).

Romidepsin has received both Fast Track and Orphan Drug Designation by the Food and Drug Administration (FDA), and Orphan Drug Designation from the European Agency for the Evaluation of Medicinal Products (EMEA) for CTCL. It has also received Orphan Drug Designation for PTCL from both the FDA and EMEA. Romidepsin is in clinical trials for a variety of other hematologic malignancies and solid tumors including hormone refractory prostate cancer, pancreatic cancer and multiple myeloma. These trials and others are being conducted by the Company or the National Cancer Institute (NCI), under a Cooperative Research and Development Agreement (CRADA) with the Company.

About Gloucester Pharmaceuticals, Inc.

Gloucester Pharmaceuticals, Inc. is a privately-held, venture-backed company that develops and commercializes innovative products for the treatment of cancer patients. Gloucester is headquartered in Cambridge, MA. For more information on Gloucester and our clinical development program visit our website at www.gloucesterpharma.com or call 888-474-2825.